Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2021

View Archived Issues

Medshine Discovery discovers ketohexokinase inhibitors

Dual GCGR and GLP-1 agonists patented by Merck & Co.

Bristol Myers Squibb patents diacylglycerol kinase alpha/zeta inhibitors

Evaluation of a mucosal vaccine based on recombinant N. lactamica expressing heterologous antigens

T-cell exhaustion is durable, but specific

Clinical trial of AP-003 in COVID-19 approved in Chile

FDA clears IND for lanraplenib in patients with AML

Discovery novel GPR119 agonist with excellent blood glucose-lowering effects

Ghent University Hybrid CAR-T cell platform has dual anti-HIV effects

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

Boehringer Ingelheim advances development of alteplase for COVID-19 ARDS

Infinity reports data on eganelisib in combination therapy for urothelial cancer and TNBC

New phase II trial evaluates Orpathsys for advanced or metastatic MET-amplified gastric cancer

JadiCell reduces lung injury in animal model replicating COVID-19 Delta variant inflammation

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

Dosing underway in phase I trial of AR degrader GT-20029 in China

Mouse model shows targeting RagC GTPase could safely treat B-cell lymphomas

Ipsen and BAKX Therapeutics partner on BKX-001

University of Oxford tests vaccine against plague in phase I

Eccogene begins first-in-human study of ECC-0509 for NASH and osteoarthritis pain

DiosCURE enters licensing agreement for single-domain antibodies against SARS-CoV-2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...